Methode Electronics Earnings Presentation Third Quarter Fiscal 2026 March 6, 2026 Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect, when made, our current views with respect to current events and financial performance. Such forward-looking statements are subject to many risks, uncertainties and factors relating to our operations and business environment, which may cause our actual results ...

Dick Warzala Chairman, President & CEO Jim Michaud Chief Financial Officer Nasdaq: ALNT March 6, 2026 Fourth Quarter & Full Year 2025 Financial Results Call SAFE HARBOR STATEMENT This presentation will discuss some non-GAAP financial measures, which the Company believes are useful in evaluating our performance. You should not consider the presentation of this additional information in isolation or as a substitute for results prepared in accordance with GAAP. The Company has provided reconciliations of compa ...

Results Conference Call 4Q25 Disclaimer and Forward-Looking Statement This presentation may contain forward-looking statements within the meaning of federal securities law that are subject to risks and uncertainties. These statements are only predictions based upon our current expectations and projections about possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminol ...

Investor Presentation March 2026 Legal Disclaimer This Investor Presentation includes "forward-looking statements" which reflect Orion Properties Inc.'s (the "Company", "Orion", "we", or "us") expectations and projections regarding future events and plans, future financial condition, results of operations, liquidity and business, including leasing and occupancy, acquisitions, dispositions, rent receipts, expected borrowings and financing costs and the payment of future dividends. Generally, the words "antic ...

2025 Performance Webcast March 6, 2026 c P-78 First oil in December 2025, in the Búzios field Paleta Petrobras (cores principais e secundárias) — Disclaimer The presentation may contain forwardlooking statements about future events that are not based on historical facts and are not assurances of future results. Such forward- looking statements merely reflect the Company's current views and estimates of future economic circumstances, industry conditions, company performance and financial results. Such terms ...

4Q25 Earnings Presentation March 6, 2026 Disclaimer and Forward Looking Statements The guidance provided in this presentation is based on information available as of March 6, 2026 and management's review of the anticipated financial results for 2026. Such guidance remains subject to change based on management's ongoing review of the Company's 2026 results and is a forward-looking statement (see below). Kingstone assumes no obligation to update this guidance. The actual results may be materially different an ...

Revolutionizing the recycling of Used Motor Oil. INVESTOR PRESENTATION – MARCH 2026 TSXV: GIII | OTCQB: ISRJF USD unless otherwise noted Forward Looking Statements & Non-GAAP Financial Measures Forward Looking Statements This presentation contains forward looking statements that reflect management's expectations regarding the future growth, results of operations, performance (both operational and financial) and business prospects and opportunities of ReGen III Corp. ("ReGen III" or the "Company"). All state ...

255 210 90 231 149 48 221 68 49 10 26 92 EQUITY STORY MAR/26 10 57 91 0 177 210 223 241 239 0 74 232 209 223 231 100 120 131 0 191 169 0 114 188 EMBRAER INVESTOR RELATIONS OUR TEAM STAY IN THE KNOW - Antonio Garcia, CFO IR Alerts 4Q25 Earnings Youtube LinkedIn X Instagram 4Q25 Backlog & Deliveries Release 2 10 57 91 0 177 210 223 241 239 255 210 90 231 149 48 221 68 49 10 26 92 0 74 232 209 223 231 100 120 131 0 191 169 0 114 188 - Gui Paiva, EAH CFO, Head IR, M&A and CVC - Patrícia Mc Knight, IR manager - ...

Summary of Conference Call Notes Company and Industry Overview - **Company**: Corning Inc. (康宁) - **Industry**: Telecommunications and Optical Communications Key Points and Arguments 1. **Springboard Plan Revision**: The revenue targets for the Springboard plan have been revised upwards to $6.5 billion for 2026 and $11 billion for 2028, driven primarily by large orders from major clients like Meta [2][3] 2. **Optical Communications Growth**: The mid-term compound annual growth rate (CAGR) guidance for enterprise networks and data centers has been increased from 25% to 30%, with full optical interconnects expected to increase the number of internal optical connections by 5 to 10 times [2][4] 3. **AI-Driven Scale-Up/Out**: The configuration of single-node GPUs is evolving from 8 to 32/72, accelerating the transition from copper to fiber optics and MMC connectors within racks [2][5] 4. **Major Order from Meta**: A significant $6 billion order has been signed with Meta, covering a complete solution including fiber, devices, and integration, with a delivery period from 2026 to 2030 [2][6] 5. **Network Recovery**: There is a resurgence in operator networks, with a surge in demand for Data Center Interconnect (DCI), supported by a partnership with Lumen that secures about 10% of the company's fiber capacity for North American network construction [2][5] 6. **Solar Business Expansion**: The solar business aims for $2.5 billion in revenue by 2028, leveraging local manufacturing advantages through the acquisition of Hemlock to reduce risks and enhance returns [2][8] 7. **Investment Framework Shift**: The focus is shifting to evaluating the long-term capacity commitments from major clients rather than just the price elasticity of non-fiber products [2][11] Additional Important Content 1. **Historical Context**: Corning was founded in Corning, New York, and has a long history in glass and optical fiber innovation, with a revenue scale consistently around $10 billion annually [3] 2. **Global Capacity Distribution**: Fiber production capacity is primarily located in North Carolina and Poland, with additional facilities in India, while jumpers and cables are mainly produced in Mexico and China [7] 3. **Specialty Materials and Environmental Technology**: The specialty materials segment covers applications in telescopes, aerospace, and consumer electronics, while environmental technology focuses on materials to reduce pollution in automotive applications [9][10] 4. **Investment Evaluation**: The evaluation of Corning should not solely focus on fiber price fluctuations but rather on stable long-term partnerships with major clients and the company's ability to deliver customized solutions [11] This summary encapsulates the critical insights from the conference call, highlighting the company's strategic direction, growth opportunities, and market dynamics.

Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [5] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [5] - R&D expenses for 2025 were $148 million, lower than in 2024 due to many late-stage trials nearing completion [6] - Cash position strengthened to approximately $1.4 billion, allowing for accelerated global development and exploration of in-licensing and M&A opportunities [4][7] Business Line Data and Key Metrics Changes - Ex-China FRUZAQLA sales grew by 26% year-over-year, totaling $366 million in in-market sales [3] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [3] - ORPATHYS and SULANDA accounted for 11% of total 2025 in-market sales, facing challenges due to competition [10] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds from Medicare Part D redesign, impacting overall performance [9] - China sales under the brand name ELUNATE experienced a -13% decline in the first half but rebounded with 33% growth in the second half [9] - The ITP market potential in China is significant, with over 250,000 actively treated patients, representing an addressable market of $500 million to $700 million [19] Company Strategy and Development Direction - The company aims to accelerate global development of ATTC programs while exploring business development opportunities [25] - Focus on expanding the hematology portfolio with new products and establishing a dedicated sales and marketing team for this specialized area [11][71] - The strategy includes potential partnerships for the ATTC platform to validate and enhance its value [50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with oncology revenue guidance set between $330 million and $450 million, reflecting strong growth expectations [7][25] - The company anticipates continued growth from new indications and the global expansion of FRUZAQLA [31] - Management highlighted the importance of maintaining a balance between existing commercial products and emerging opportunities from the ATTC platform [52] Other Important Information - The company has advanced two ATTC programs into clinical trials, with significant market potential anticipated [4] - The SAFFRON and SANOVO readouts are expected in mid-2026, which are critical for future growth [31][24] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong growth expectations, particularly from new indications and continued recovery in sales [30][31] Question: What is the status of the SAFFRON readout? - The SAFFRON readout is expected to occur in mid-2026 [31][36] Question: Can you provide details on the ATTC platform candidates? - A251 is currently enrolling HER2 expressing solid tumor patients, focusing on post-HER2 treatment settings [31] Question: How are commercial dynamics expected to stabilize in 2026? - Management noted that turnover rates have decreased and the sales team has been restructured to focus on top-tier hospitals, which should improve performance [41][42] Question: What is the impact of MET testing adoption on savolitinib? - No additional information was provided on the influence of MET testing adoption on savolitinib uptake [48] Question: What is the partnering strategy for the ATTC platform? - The company is considering licensing out some programs while maintaining control over others to maximize long-term value [50] Question: What is the guidance for R&D expenses this year? - Management indicated a desire to ramp up R&D investment to a range of $250 million to $300 million [60] Question: Can you elaborate on the in-licensing and M&A strategy? - The company is open to in-licensing late-stage commercial assets or complementary assets, given its strong cash position [63] Question: How will the move into hematology products affect sales and marketing investments? - A new business unit with dedicated sales and marketing capabilities has been established to address the hematology market [71]